Systemic Scleroderma Treatment Market, By Drug Class (Immunosuppressant, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Calcium Channel Blockers, Prostacyclin Analogues, and Others), By Type (Limited Systemic Sclerosis, Diffused Sy

Systemic Scleroderma Treatment Market, By Drug Class (Immunosuppressant, Phosphodiesterase 5 inhibitors - PHA, Endothelin Receptor Antagonists, Calcium Channel Blockers, Prostacyclin Analogues, and Others), By Type (Limited Systemic Sclerosis, Diffused Systemic Sclerosis, and Sine Sclerosis), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Systemic scleroderma is a chronic autoimmune connective tissue disorder that causes hardening and tightening of the skin and connective tissues. It is characterized by the overproduction of collagen in the cells and tissues of the body leading to fibrosis or scarring. Currently, there is no cure for systemic scleroderma and the treatment options are limited to manage its symptoms and slow disease progression. The systemic scleroderma treatment market comprises drugs, therapies, medical devices and other products being used to treat this condition. With rising prevalence and limited treatment options, this market is poised to grow significantly in the coming years.

Market Dynamics:

The global systemic scleroderma treatment market is driven by the increasing incidence and prevalence of systemic scleroderma worldwide. According to Scleroderma Foundation, around 300,000 people in the U.S. and millions worldwide suffer from scleroderma. However, limited understanding of disease etiology, scarce treatment options, and lack of approved drugs for systemic forms pose challenges to market growth. Nonetheless, ongoing research on novel drugs and therapies holds promise to widen the treatment landscape. Furthermore, rising healthcare expenditures in major markets will facilitate market expansion through 2030.

Key Features of the Study:

• This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global systemic scleroderma treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GSK plc, Certa Therapeutics, Aisa Pharma, Inc., Corbus Pharmaceuticals, AbbVie, Inc., Biogen, Novartis AG, AstraZeneca, Celgen Corporation, ONO PHARMACEUTICAL CO., LTD., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH., and MediciNova, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market

Market Segmentation

• Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
• Immunosuppressant
• Phosphodiesterase 5 inhibitors - PHA
• Endothelin Receptor Antagonists
• Calcium Channel Blockers
• Prostacyclin Analogues
• Others
• Type Insights (Revenue, USD Bn, 2019 - 2031)
• Limited Systemic Sclerosis
• Diffused Systemic Sclerosis
• Sine Sclerosis
• Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
• Oral
• Parenteral
• Others
• Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• GSK plc
• Certa Therapeutics
• Aisa Pharma, Inc.
• Corbus Pharmaceuticals
• AbbVie, Inc.
• Biogen
• Novartis AG
• AstraZeneca
• Celgen Corporation
• ONO PHARMACEUTICAL CO., LTD.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim International GmbH.
• MediciNova, Inc.